Evolution of the Average Target: Cencora, Inc.

Evolution of the Target Price: Cencora, Inc.

Changes in Analyst Recommendations: Cencora, Inc.

ee71e6cfbf0ac30.rl_XQ-hftIsgT6Erc3QrNcoLjl-GoMjGowFmRFehg98.gzuYC5s-0rpHK8pkMgd7XLtE-Wf-9oXyxE8KCBTZ2Yj0CIV7jGbx7xIokQ~518143a7cf49063c37c259f0888b9003
06-24 Argus Adjusts Price Target on Cencora to $340 From $4000, Maintains Buy Rating MT
06-24 BofA Adjusts Price Target on Cencora to $285 From $280 MT
06-10 Barclays Cuts Cencora Price Target to $350 From $425, Maintains Overweight Rating MT
05-21 Baird Adjusts Price Target on Cencora to $337 From $339, Maintains Outperform Rating MT
05-11 Wells Fargo Adjusts Price Target on Cencora to $331 From $429 MT
05-08 McKesson's Fiscal 2027 Guidance 'Encouraging,' Cencora Selloff Overdone, Morgan Stanley Says MT
05-08 Morgan Stanley Lowers Price Target on Cencora to $342 From $400, Keeps Overweight Rating MT
05-07 UBS Adjusts Price Target on Cencora to $412 From $410, Maintains Buy Rating MT
04-28 William Blair Initiates Cencora at Market Perform MT
04-08 Evercore ISI Adjusts Price Target on Cencora to $360 From $420, Maintains Outperform Rating MT
03-19 Baird Adjusts Price Target on Cencora to $420 From $415, Maintains Outperform Rating MT
03-02 Leerink Partners Adjusts Price Target on Cencora to $447 From $410, Maintains Outperform Rating MT
02-13 Barclays Adjusts Cencora Price Target to $425 From $400, Maintains Overweight Rating MT
02-10 Wells Fargo Adjusts Price Target on Cencora to $429 From $405, Maintains Overweight Rating MT
02-10 JPMorgan Adjusts Price Target on Cencora to $419 From $417, Maintains Overweight Rating MT
02-05 Evercore ISI Adjusts Price Target on Cencora to $420 From $440, Maintains Outperform Rating MT
01-29 Cencora Shares Rise After Morgan Stanley Upgrade MT
01-29 Morgan Stanley Upgrades Cencora to Overweight From Equalweight, Adjusts PT to $400 From $361 MT
01-22 Jefferies Upgrades Cencora to Buy From Hold, Adjusts Price Target to $440 From $330 MT
01-13 Baird Adjusts Cencora Price Target to $415 From $392, Maintains Outperform Rating MT
01-05 Drug Distributors Poised for Growth Amid Emerging Risks, BofA Says MT
12-15 Baird Adjusts Cencora Price Target to $392 From $395, Maintains Outperform Rating MT
12-15 Evercore ISI Adjusts Price Target on Cencora to $420 From $400, Maintains Outperform Rating MT
11-28 Argus Adjusts Price Target on Cencora to $400 From $340, Maintains Buy Rating MT
11-25 Deutsche Bank Raises Price Target on Cencora to $389 From $371, Keeps Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+22.32%
+24.99%
+21.71%
+16.31%
+17.42%
+35.42%
+24.17%
+3.53%
+21.96%
+35.4%
Average +22.32%
Weighted average by Cap. +22.51%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
286.13USD
Average target price
351.00USD
Spread / Average Target
+22.67%
High Price Target
412.00USD
Spread / Highest target
+43.99%
Low Price Target
285.00USD
Spread / Lowest Target
-0.39%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Argus
BofA Securities
Barclays
Baird
Wells Fargo Securities
Morgan Stanley
UBS
William Blair & Co.
Evercore ISI
Leerink Partners
JPMorgan Chase
Jefferies & Co.
Deutsche Bank Securities
TD Cowen
Mizuho Securities
Citigroup
Nephron Research
Credit Suisse
Cowen
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
286.13USD
Average target price
351.00USD
Spread / Average Target
+22.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COR Stock
  4. Consensus Cencora, Inc.